Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking

Hepatology

Volumn 54, Issue 6, 2011, Pages 1966-1974

  Wu, Chuanghong ^a,b   Gilroy, Richard ^a   Taylor, Ryan ^a   Olyaee, Mojtaba ^a   Abdulkarim, Bashar ^a   Forster, Jameson ^a   O'Neil, Maura ^a   Damjanov, Ivan ^a   Wan, Yu Jui Yvonne ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; FATTY ACID; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; HETERODIMER; INTERLEUKIN 10; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RETINOID X RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ADULT; AGE; AGED; ARTICLE; BILE ACID SYNTHESIS; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; DRINKING BEHAVIOR; FEMALE; GENDER; GENE EXPRESSION; GENOTYPE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS INFECTION; VIRUS REPLICATION;

ADULT; AGED; ALCOHOL DRINKING; FATTY ACIDS; FEMALE; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; PPAR ALPHA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOID X RECEPTOR ALPHA; RNA, VIRAL; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 82455162662     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24645     Document Type: Article

References (55)

1. Kim WR. The burden of hepatitis C in the United States. HEPATOLOGY 2002; 36( 5 Suppl 1): S30-S34.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
5. Poordad F, McCone JJr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
6. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
7. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
8. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
9. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-6928.
10. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130.
11. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
12. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-1669.
13. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. HEPATOLOGY 2011; 53: 1023-1034.
14. Wang K, Wan YJ. Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood) 2008; 233: 496-506.
15. Raglow Z, Thoma-Perry C, Gilroy R, Wan YJ. The interaction between HCV and nuclear receptor-mediated pathways. Pharmacol Ther 2011; 132: 30-38.
16. Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-1125.
17. Peters MG, Terrault NA. Alcohol use and hepatitis C. HEPATOLOGY 2002; 36( 5 Suppl 1): S220-S225.
18. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004; 24: 305-315.
19. Gyamfi MA, Wan YJ. Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp Biol Med (Maywood) 2010; 235: 547-560.
20. Mello T, Polvani S, Galli A. Peroxisome proliferator-activated receptor and retinoic x receptor in alcoholic liver disease. PPAR Res 2009; 2009: 748174.
21. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
22. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766-12771.
23. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010; 59: 1279-1287.
24. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-2830.
25. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002; 277: 11019-11025.
26. Burris TP. Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Mol Endocrinol 2008; 22: 1509-1520.
27. Pearce KH, Iannone MA, Simmons CA, Gray JG. Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling. Drug Discov Today 2004; 9: 741-751.
28. Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, et al. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 2000; 20: 4436-4444.
29. Wan YJ, Cai Y, Lungo W, Fu P, Locker J, French S, et al. Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice. J Biol Chem 2000; 275: 28285-28290.
30. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-342.
31. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003; 100: 15924-15929.
32. Liu S, Hatano B, Zhao M, Yen CC, Kang K, Reilly SM, et al. Role of peroxisome proliferator-activated receptor {delta>/{beta> in hepatic metabolic regulation. J Biol Chem 2011; 286: 1237-1247.
33. Ma X, Xu L, Wang S, Cui B, Li X, Xu J, et al. Deletion of steroid receptor coactivator-3 gene ameliorates hepatic steatosis. J Hepatol 2011; 55: 445-452.
34. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun 2007; 355: 883-888.
35. Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett 2009; 583: 2720-2726.
36. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 2008; 89: 1225-1230.
37. Trauner M. A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. HEPATOLOGY 2007; 46: 1-5.
38. Scholtes C, Diaz O, Icard V, Kaul A, Bartenschlager R, Lotteau V, et al. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J Hepatol 2008; 48: 192-199.
39. Chang KO, George DW. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J Virol 2007; 81: 9633-9640.
40. Dong B, Saha PK, Huang W, Chen W, Abu-Elheiga LA, Wakil SJ, et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci U S A 2009; 106: 18831-18836.
41. Wan YJ, Morimoto M, Thurman RG, Bojes HK, French SW. Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease. Life Sci 1995; 56: 307-317.
42. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. HEPATOLOGY 2004; 40: 972-980.
43. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278: 27997-28004.
44. Garcia-Villafranca J, Guillen A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 2008; 90: 460-466.
45. Ye L, Wang S, Wang X, Zhou Y, Li J, Persidsky Y, et al. Alcohol impairs interferon signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytes. Drug Alcohol Depend 2010; 112: 107-116.
46. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-425.
47. Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab 2007; 5: 405-407.
48. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009; 94: 3594-3601.
49. Morari J, Torsoni AS, Anhe GF, Roman EA, Cintra DE, Ward LS, et al. The role of proliferator-activated receptor gamma coactivator-1alpha in the fatty-acid-dependent transcriptional control of interleukin-10 in hepatic cells of rodents. Metabolism 2010; 59: 215-223.
50. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99: 15669-15674.
51. Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. HEPATOLOGY 2008; 48: 1396-1403.
52. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, et al. Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol 2010; 45: 523-536.
53. Fujita N, Kaito M, Tanaka H, Horiike S, Adachi Y. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 2280.
54. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, et al. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006; 13: 441-448.
55. Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J 2005; 24: 2624-2633.